tbuckley/cabot-search huggingface dataset:
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
Authors: Jennifer G. Robinson, Robert S. Rosenson, Michel Farnier, Umesh Chaudhari, William J. Sasiela, Laurence Merlet, Kathryn Miller, John J.P. Kastelein
Journal: Journal of the American College of Cardiology (2017)

Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low levels when added to background lipid-lowering therapy.The safety of alirocumab was evaluated in patients with at least 2 consecutive LDL-C values <25 or <15 mg/dl in the ODYSSEY program, with follow-up as long as 104 weeks.Pooled data from 14 trials were analyzed (double-blind treatment 8 to 104 weeks; n = 3,340 alirocumab, n = 1,894 control [placebo or ezetimibe]; representing 4,029 [alirocumab] and 2,114 [control] double-blind patient-years' exposure).In alirocumab-treated patients, 839 (25.1%) achieved 2 consecutive LDL-C values <25 mg/dl, and 314 (9.4%) achieved <15 mg/dl. Baseline LDL-C was lower (mean 100.3 vs. 134.3 mg/dl) in patients with LDL-C <25 versus ≥25 mg/dl. Similar rates of adverse events occurred in patients achieving LDL-C <25 and <15 mg/dl (72.7% and 71.7%, respectively), compared with 76.6% in those who did not achieve LDL-C <25 mg/dl. Neurological and neurocognitive events were similar among the 3 groups. In a propensity score analysis, the rate of cataracts was higher in patients with LDL-C <25 mg/dl (2.6%) versus ≥25 mg/dl (0.8%; hazard ratio: 3.40; 95% confidence interval: 1.58 to 7.35). However, no difference in cataract incidence was observed between pooled alirocumab and control groups.LDL-C levels <25 or <15 mg/dl on alirocumab were not associated with an increase in overall treatment-emergent adverse event rates or neurocognitive events, although cataract incidence appeared to be increased in the group achieving LDL-C levels <25 mg/dl. (Pooled analyses of already reported trials; NCT01288443, NCT01288469, NCT01266876, NCT01812707, NCT01507831, NCT01617655, NCT01623115, NCT01709500, NCT01644175, NCT01644188, NCT01730040, NCT01730053, NCT01644474, and NCT01709513).
Identification of a De Novo UNC13D L1000P Mutation in a Familial Hemophagocytic Lymphohistiocytosis Patient
Authors: Hongxing Liu, Fang Wang, Juan Zhu, Hui Wang, Ping Wu, Wen Teng, Xu Han, Jianfeng Zhang, Ping Zhu, Tong Wu, Chunrong Tong
Journal: Blood (2011)
Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury
Authors: Daniel F. Carr, Seyoum Ayehunie, Andrea Davies, Carrie A. Duckworth, Stephanie French, Neil Hall, Syed Hussain, Howard R. Mellor, Alan Norris, B. Kevin Park, Alexander Penrose, D. Mark Pritchard, Chris S. Probert, Shashi Ramaiah, Claire Sadler, Michael Schmitt, Alison Shaw, James E. Sidaway, Robert G. Vries, Matthew Wagoner, Munir Pirmohamed
Journal: Pharmacology & Therapeutics (2017)
Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness.
Authors: Amy Pickar Abernethy, Jean Kutner, Patrick Jud Blatchford, Christine Ritchie, Diane Fairclough, Laura Hanson, Janet Bull
Journal: Journal of Clinical Oncology (2014)

LBA9514 Background: For patients with life-threatening illness such as advanced cancer, optimal management of longstanding medications prescribed for comorbid illness is uncertain. Risks may outweigh benefits; e.g., benefits from HMG Co-A reductase inhibitors (“statins”) may take years to accrue and may not be relevant for a person with limited prognosis. Is it safe to discontinue statins for the patient with less than a year to live? Methods: This was a multicenter, unblinded pragmatic trial. At enrollment, participants were randomized (1:1) to discontinue or continue their statin medication. Eligible patients were adults with advanced life-limiting illness on a statin for ≥3 months for primary or secondary prevention, a life expectancy of greater than one month, and evidence of recent deterioration in performance status. Outcomes measured at baseline and at least monthly included survival, cardiovascular-related events, quality of life (QOL), symptoms, and polypharmacy. Rate of death within 60 days of randomization was the primary outcome. Results: 381 patients were enrolled (189 discontinue statins; 192 continue statins). Mean age was 74 years (SD 12); 22% were cognitively impaired; 49% had cancer as the primary diagnosis; and, 69% had used statins for &gt;5 years. Rate of death within 60 days was not statistically different between groups (discontinue vs. continue, 23.8% vs. 20.3%, 90% CI -3.5% to 10.5%, p=0.36). The group discontinuing statins had longer median time-to-death (229 days [90% CI 186–332] vs. 190 days [90% CI 170-257]; p=0.60). Total QOL was significantly better among the group discontinuing statins (McGill QOL: 7.11 vs. 6.85, p=0.037) and there were fewer symptoms in this group (Edmonton Symptom Assessment Scale: 25.2 vs. 27.4, p=0.128). People in the discontinue statins group took significantly fewer medications (10.1 vs. 10.8, p = 0.034). Few participants in either group experienced cardiovascular events (13 vs. 11). Conclusions: In the setting of life-limiting illness such as advanced cancer, it is unlikely that harm will accrue when statins being used for primary or secondary prevention are discontinued; these patients may even benefit. Clinical trial information: NCT01415934.
Preliminary results of a phase II trial of FOLFOX4 regimen in Chinese patients with unresectable primary liver cancer
Authors: S. K. Qin, Y. J. Wang, Q. Wu, B. C. Xing
Journal: Journal of Clinical Oncology (2006)

14065 Background: Primary liver cancer (PLC) is the 3 rd most common cancer in whole China. Development of systemic chemotherapy for the patients not eligible for operation as well as TACE commonly have been required. Oxalipaltin (Eloxatin)+ 5-FU/LV, namely FOLFOX 4 regimen was tried to investigate its efficacy and safety in inoperable PLC. Methods: It was an open-label, single arm and multi-center phase II study to explore RR, DCR,TTP and MST. All the pts had pathologically confirmed inoperable PLC with/without distant metastasis. The pts were treated with the standard FOLFOX 4 regimen, that is OXA 85mg/m 2 d1; LV 200mg/m 2 IV 2hrs d1,2; 5-FU 400mg/m 2 bolus, d1,2 and 5-FU 600mg/m 2 CIV 22hrs d1,2; q2w upto 6 cycles or until progression. Tumor evaluation was done every 6 weeks using RECIST criteria. Neurotoxicity was evaluated by Eloxatin specific neurotoxicity criteria (Sanofi-Aventis Co.Ltd) and other toxicities by the NCI CTC AE version 2.0. Results: From July 2004 to Sep. 2005, 27 pts (21 male, 6 female) were recruited from the 4 cancer centers with average age of 56 ±13 years old. 25 patients (92.6%) had hepatocellular carcinoma, and 2 (7.4%) cholangiocellular carcinoma. 15 pts (55.6%) had metastatic disease. 1 pt received liver transplantation before inclusion. The median number of cycles was 4 per pt. 26 pts were evaluable for efficacy and safety. The RR was 19.2% (5/26; 1 CR and 4 PR), and DCR 57.7% (15/26; including 10 SD). 4 of the 5 responsive pts had hepatocellular carcinoma, and 1 had cholangiocarcinoma. Serum AFP level was significantly decreased (mean 131,890.4ug/dl at the baseline and 1,298.6ug/dl after 6 cycles) for the first 16 pts. The first 16 pts’ safety data were available in detail: 11 NCI grade 3/4 events were observed from a total of 76 cycles administered: including 5 neutropenia, 3 leucopenia, 1 thrombocytopenia, 1 infection and 1 liver dysfunction. Grade II &amp; III neurotoxicity was found in 3 &amp; 2 patients respectively. The TTP,MST and further safety data were under follow-up. Conclusions: The preliminary data of the FOLFOX 4 regimen for the advanced Chinese pts with inoperable PLC have shown encouraging results with the better efficacy and favorable safety profile. Further exploration in this area is warranted, especially in hepatocellular carcinoma. No significant financial relationships to disclose.
Influence of FcγRIIA H131R Polymorphism on the Risk of Thrombosis in HIT and Variable Effect of Normal IgG on Platelet Activation
Authors: Jerôme Rollin, Claire Pouplard, Dorothee Leroux, Armand Saada, Céline Behier, Valérie Gouilleux Gruart, Gilles Thibault, Yves Gruel
Journal: Blood (2014)
Ileostomy As a Treatment Option in Patients with Refractory Acute Gastro-Intestinal Graft Versus Host Disease
Authors: Stéphanie Guidez, Valerie Coiteux, Romain Gerard, Remy Dulery, Leonardo Magro, Ibrahim Yakoub-Agha, Alain Saudemont, David Seguy
Journal: Blood (2014)
A Novel 2 Amino Acids Deletion in the Leucine Zipper Domain of C/EBPε Leads to Neutrophil-Specific Granule Deficiency (SGD)
Authors: Tadayuki Akagi, Taizo Wada, Masahiro Muraoka, Tomoko Toma, Kenzo Kaji, Kazunaga Agematsu, H. Phillip Koeffler, Takashi Yokota, Akihiro Yachie
Journal: Blood (2014)
Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis
Authors: Nicola Veronese, Emanuele Cereda, Brendon Stubbs, Marco Solmi, Claudio Luchini, Enzo Manzato, Giuseppe Sergi, Peter Manu, Tamara Harris, Luigi Fontana, Timo Strandberg, Helene Amieva, Julien Dumurgier, Alexis Elbaz, Christophe Tzourio, Monika Eicholzer, Sabine Rohrmann, Claudio Moretti, Fabrizio D’Ascenzo, Giorgio Quadri, Alessandro Polidoro, Roberto Alves Lourenço, Virgilio Garcia Moreira, Juan Sanchis, Valeria Scotti, Stefania Maggi, Christoph U. Correll
Journal: Ageing Research Reviews (2017)
Evidence for a role of eosinophils in blister formation in bullous pemphigoid
Authors: E. de Graauw, C. Sitaru, M. Horn, L. Borradori, S. Yousefi, H.‐U. Simon, D. Simon
Journal: Allergy (2017)

Bullous pemphigoid (BP) is an autoimmune bullous disease of the skin characterized by subepidermal blister formation due to tissue-bound and circulating autoantibodies to the hemidesmosomal antigens BP180 and BP230. Although eosinophils and their toxic mediators are found abundantly in BP lesions, their role in blister formation has remained unclear.To investigate the role of eosinophils in the pathogenesis of BP with a specific focus on blister formation and to define conditions inducing dermal-epidermal separation (DES).In an ex vivo human model of BP, normal human skin cryosections were incubated with purified human peripheral blood eosinophils with or without activation in the presence or absence of BP autoantibodies, brefeldin A, diphenyleneiodonium, DNase or blocking F(ab')2 fragments to CD16, CD18, CD32 and CD64. Dermal-epidermal separation was assessed by light microscopy studies and quantified using Fiji software.Following activation with IL-5 and in the presence of BP autoantibodies, eosinophils induced separation along the dermal-epidermal junction of ex vivo skin. Dermal-epidermal separation was significantly reduced by blocking any of the following: Fcγ receptor binding (P = 0.048), eosinophil adhesion (P = 0.046), reactive oxygen species (ROS) production (P = 0.002), degranulation (P < 0.0001) or eosinophil extracellular trap (EET) formation (P = 0.048).Our results provide evidence that IL-5-activated eosinophils directly contribute to BP blister formation in the presence of BP autoantibodies. Dermal-epidermal separation by IL-5-activated eosinophils depends on adhesion and Fcγ receptor activation, requires elevated ROS production and degranulation and involves EET formation. Thus, targeting eosinophils may be a promising therapeutic approach for BP.
Experiences with Caspofungin Plus Posaconazole in Immunocompromised Adults with Invasive Aspergillosis (IA) Refractory to Prior Standard Therapy.
Authors: Joachim Dahlke, Tatjana Zabelina, Heinrich Lellek, Alexander Muth, Olga Waschke, Christine Wolschke, Ingo Sobottka, Nicolaus Kroeger, Axel R. Zander
Journal: Blood (2006)
The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis
Authors: P J Dodd, A J Prendergast, C Beecroft, B Kampmann, J A Seddon
Journal: Thorax (2017)

<h3>Background</h3> Children (&lt;15 years) are vulnerable to TB disease following infection, but no systematic review or meta-analysis has quantified the effects of HIV-related immunosuppression or antiretroviral therapy (ART) on their TB incidence. <h3>Objectives</h3> Determine the impact of HIV infection and ART on risk of incident TB disease in children. <h3>Methods</h3> We searched MEDLINE and Embase for studies measuring HIV prevalence in paediatric TB cases ('TB cohorts') and paediatric HIV cohorts reporting TB incidence ('HIV cohorts'). Study quality was assessed using the Newcastle-Ottawa tool. TB cohorts with controls were meta-analysed to determine the incidence rate ratio (IRR) for TB given HIV. HIV cohort data were meta-analysed to estimate the trend in log-IRR versus CD4%, relative incidence by immunological stage and ART-associated protection from TB. <h3>Results</h3> 42 TB cohorts and 22 HIV cohorts were included. In the eight TB cohorts with controls, the IRR for TB was 7.9 (95% CI 4.5 to 13.7). HIV-infected children exhibited a reduction in IRR of 0.94 (95% credible interval: 0.83–1.07) per percentage point increase in CD4%. TB incidence was 5.0 (95% CI 4.0 to 6.0) times higher in children with severe compared with non-significant immunosuppression. TB incidence was lower in HIV-infected children on ART (HR: 0.30; 95% CI 0.21 to 0.39). Following initiation of ART, TB incidence declined rapidly over 12 months towards a HR of 0.10 (95% CI 0.04 to 0.25). <h3>Conclusions</h3> HIV is a potent risk factor for paediatric TB, and ART is strongly protective. In HIV-infected children, early diagnosis and ART initiation reduces TB risk. <h3>Trial registration number</h3> CRD42014014276.
Cutting hospital beds would be “lunacy,” warns senior emergency doctor
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Plans to reduce bed capacity in some NHS hospitals are “lunacy” against the current backdrop of rising demand and high occupancy rates, the Royal College of Emergency Medicine’s vice president has said.

A number of the 44 sustainability and transformation plans (STPs) that are currently being implemented across England have proposed reductions in inpatient beds as part of long term strategies to invest more in out of hospital services.1

But the college’s vice president, Chris Moulton, told The BMJ that reducing the number of …
Efficacy of oxymatrine for treatment and relapse suppression of severe plaque psoriasis: results from a single-blinded randomized controlled clinical trial
Authors: H. Zhou, H.-J. Shi, J. Yang, W.-G. Chen, L. Xia, H.-B. Song, K.-P. Bo, W. Ma
Journal: British Journal of Dermatology (2017)

Drugs that are currently used in the treatment of psoriasis are associated with drawbacks such as rapid recrudescence, high costs and unwanted side‐effects. Oxymatrine has a long history of clinical use in the treatment of hepatitis and cancer in China. To explore the efficacy and safety of intravenous oxymatrine in patients with severe plaque psoriasis. A total of 67 patients were randomly allocated to receive oxymatrine injections (0.6 g per day for 8 weeks) or acitretin capsules (0.75 mg kg−1 per day from week 0 to week 2 and 20–30 mg per day from week 3 to week 8) and followed up for another 24 weeks. The primary end point was the percentage of patients with ≥ 50% reduction of Psoriasis Area and Severity Index (PASI 50) at week 32. The secondary end points included the skin classification grade and the Dermatology Quality of Life Index (DLQI) score. Side‐effects were recorded throughout the whole study to assess the safety profile. Treatment with oxymatrine or acitretin for 8 weeks significantly decreased PASI score, skin classification grade and DLQI score (P < 0.001), with no significant differences between the oxymatrine and acitretin groups in terms of PASI 50. However, at week 32, the relapse rate in the oxymatrine group was significantly lower than that of the acitretin group (P < 0.001). Moreover, while there was an increase in the number of patients with metabolic abnormalities in the acitretin group, a significant reduction was observed in the oxymatrine group. Furthermore, rates of adverse reactions were significantly decreased in the oxymatrine group compared with that of the acitretin group (P < 0.001). Treatment with oxymatrine effectively ameliorated severe plaque psoriasis, and was accompanied by only minor adverse effects.
Underperforming Big Ideas in Biomedical Research
Authors: Daniel G. Miller, Dean F. Sittig
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Expression of ERK1/ERK2 MAP Kinase, Protein Kinase C and Akt Kinase by Lymphoid Malignant Cells.
Authors: Ikuo Murohashi, Takashi Takahashi, Noriko Ihara, Daisuke Wakao, Fumiharu Yagasaki, Yhuichi Nakamura, Nobutaka Kawai, Akira Matsuda, Itsuro Jinnai, Masami Bessho
Journal: Blood (2005)
Wearable Technology and Long-term Weight Loss
Authors: Corrine I. Voils, Ryan J. Shaw
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients.
Authors: Tom E. Howard, Deepa K. Machiah, Kevin R. Viel, Cynthia Channel, Afshin Ameri, Rathi V. Iyer, Ray G. Watts, Charles Lutcher, Joanna Davis, Thomas C. Abshire, Laura Almasy
Journal: Blood (2005)
Limited PET-CT May Be Adequate for Interim and End of Therapy Response Assessment in Patients with Early Stage Hodgkin and Aggressive Non-Hodgkin Lymphoma - A Retrospective Single Center Study
Authors: Ofir Wolach, Hana Berenstine, Yonatan Edel, Osnat Bairey, Ofer Shpilberg, David Groshar, Meir Lahav
Journal: Blood (2011)
Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Authors: Azra Raza, Naomi Galili, Scott Smith, John E. Godwin, Ralph Boccia, Han Myint, Daruka Mahadevan, Deborah Mulford, Mark Rarick, Mary Ann Allison, Ostap Melnyk, Lisa Meng, Marsha Jones, Gail Brown, Shelby A Young, Mikkael A. Sekeres
Journal: Blood (2010)
Serum Protein Profiling with Mass Spectrometry for the Diagnosis of Myelodysplastic Syndromes.
Authors: Manuel Aivado, Dimitrios Spentzos, Ulrich Germing, Gil Alterovitz, Xiao-Ying Meng, Franck Grall, Aristoteles A.N. Giagounidis, Giannoula Klement, Ulrich Steidl, Hasan H. Otu, Christof Iking-Konert, Akos Czibere, Wolf C. Prall, Michelle Shayne, Marco F. Ramoni, Norbert Gattermann, Constantine S. Mitsiades, Rainer Haas, Eric T. Fung, Towia A. Libermann
Journal: Blood (2004)
PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells
Authors: Niina Ueno, Shikiko Ueno, Shinya Endo, Nao Nishimura, Hiro Tatetsu, Shinya Hirata, Hiroaki Mitsuya, Yutaka Okuno
Journal: Blood (2015)
Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.
Authors: Steven M Horwitz, Youn H. Kim, Francine M Foss, Jasmine M. Zain, Patricia Myskowski, Mary Jo Lechowicz, David C. Fisher, Andrei Shustov, Nancy L. Bartlett, Maria L Delioukina, Tony Koutsoukos, Steven M. Fruchtman, Owen A. O'Connor, Madeleine Duvic
Journal: Blood (2010)
BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
Authors: Mansi Parasramka, Irene K. Yan, Xue Wang, Phuong Nguyen, Akiko Matsuda, Sayantan Maji, Catherine Foye, Yan Asmann, Tushar Patel
Journal: Molecular Cancer (2017)

Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1 expression on tumor cell behavior and therapeutic sensitivity to identify rationale therapeutic strategies. The impact of BAP1 expression on sensitivity to therapeutic agents was evaluated in CCA cells with a 7-fold difference in BAP1 expression (KMBC-low, HuCCT1-high) and genetically engineered haplo-insufficient BAP1 knockout cells. We also identified long non-coding RNA genes associated with loss of BAP1 and their role in therapeutic sensitivity. Sensitivity to gemcitabine was greater in low BAP1 expressing or BAP1 knockout cells compared with the high BAP1 expressing cells or control haplo-insufficient cells respectively. Similar results were observed with TSA, olaparib, b-AP15 but not with GSK126. A differential synergistic effect was observed in combinations of gemcitabine with olaparib or GSK126 in KMBC cells and TSA or bAP15 in HuCCT1 cells, indicating BAP1 dependent target-specific synergism and sensitivity to gemcitabine. A BAP1 dependent alteration in expression of lncRNA NEAT-1 was identified by RT-PCR based lncRNA expression profiling, and an inverse relationship between this lncRNA and BAP1 was observed in analysis of the Tumor Cancer Genome Atlas cholangiocarcinoma dataset. Exogenous modulation of NEAT-1 and/or BAP1 expression altered tumor cell phenotype and modulated sensitivity to gemcitabine. NEAT-1 is a downstream effector of gemcitabine sensitivity in CCA. The expression of BAP1 is a determinant of sensitivity to therapeutic drugs that can be exploited to enhance responses through combination strategies.
Primary CNS Lymphoma - High-Dose-Chemotherapy with Autologous PBSCT and Hyperfractionated Radiotherapy as First-Line-Therapy - Results of a Multicenter Phase II Study.
Authors: Gerald Illerhaus, Reinhard Marks, Guenther Derigs, Christan Peschel, Norbert Frickhofen, Roland Guttenberger, Thomas Kubin, Christoph B. Ostertag, Juergen Finke
Journal: Blood (2005)